PPAR α agonist fenofibrate reduced the secreting load of β -cells in hypertriglyceridemia patients with normal glucose tolerance

Hypertriglyceridemia is an important risk factor associated with insulin resistance and β-cell dysfunction. this study investigated the effects of hypertriglyceridemia and fenofibrate treatment on insulin sensitivity and β-cell function in subjects with normal glucose tolerance. a total of 1974 subjects with normal glucose tolerance were divided into the normal tg group (ntg group,n = 1 302) and hypertriglyceridemia group (htg group,n = 672). next,92 patients selected randomly from 672 patients with hypertriglyceridemia were assigned to a 24-week fenofibrate treatment. the htg group had increased waist circumference (wc),body mass index (bmi),homeostasis model assessment of insulin resistance (homa-ir),and homeostasis model assessment of β-cell function (homa-β) and decreased high-density lipoprotein cholesterol (hdl-c) compared with the ntg group (all p < 0.01). the 24-week fenofibrate treatment significantly decreased the wc,bmi,tg,homa-ir,and homa-β levels and increased the hdl-c levels in the patients with hypertriglyceridemia (wc,bmi,and homa-ir: p < 0.05; tg,hdl-c,and homa-β: p < 0.01). the fenofibrate treatment significantly alleviated insulin resistance and reduced the secreting load of β-cells in the hypertriglyceridemia patients with normal glucose tolerance. © 2016 jia liu et al.